Gomulkiewicz Agnieszka, Podhorska-Okolow Marzena, Szulc Rafal, Smorag Zbigniew, Wojnar Andrzej, Zabel Maciej, Dziegiel Piotr
Department of Histology and Embryology, Wroclaw Medical University, Wroclaw, Poland.
Folia Histochem Cytobiol. 2010 Jan;48(2):242-8. doi: 10.2478/v10042-010-0011-5.
Our study aimed at examining significance of metallothionein (MT) expression in ductal breast cancers by determination of a relationship between expression of MT protein (MT-1/2) and selected prognostic factors, including grade of histological differentiation (G), expression of Ki-67 proliferative antigen, expression of estrogen receptors (ER) and progesterone receptors (PgR) and expression of HER-2 receptor. Material for the studies involved 54 samples of invasive ductal breast cancer, manifesting malignancy grades of G1-G3. In paraffin sections of examined tumours immunohistochemical reactions were performed using specific antibodies directed to MT, Ki-67, ER, PgR or HER-2. Intensity of MT-specific immunohistochemical reactions was measured using the semiquantitative IRS scale of Remmele. Intensity of colour reactions targeted at Ki-67, ER, PgR was evaluated scoring proportions of positive cells, while HER-2-specific reactions were evaluated in the scale of 0-3 points. The lowest level of MT expression was detected in breast cancer cases of G1 malignancy grade (G1 vs G3 p=0.020). A positive correlation between MT and Ki-67 antigen expression (r=0.32, p=0.019) was disclosed. Moreover, MT expression exhibited negative correlations with expression of ER (r=-0.35, p=0.008) and PgR (r=-0.27, p=0.046). No relationships could be detected between expression of MT and expression of HER-2 (r=0.12, p=0.37). The obtained results suggest that MT expression might be helpful in prognostic evaluation of ductal breast cancers.
我们的研究旨在通过确定金属硫蛋白（MT）蛋白（MT-1/2）的表达与选定的预后因素之间的关系，来研究MT表达在乳腺导管癌中的意义，这些预后因素包括组织学分化程度（G）、Ki-67增殖抗原的表达、雌激素受体（ER）和孕激素受体（PgR）的表达以及HER-2受体的表达。研究材料包括54例浸润性乳腺导管癌样本，恶性程度为G1-G3级。在被检查肿瘤的石蜡切片中，使用针对MT、Ki-67、ER、PgR或HER-2的特异性抗体进行免疫组化反应。使用Remmele的半定量IRS量表测量MT特异性免疫组化反应的强度。针对Ki-67、ER、PgR的显色反应强度通过对阳性细胞比例进行评分来评估，而HER-2特异性反应则在0-3分的量表上进行评估。在G1恶性程度的乳腺癌病例中检测到最低水平的MT表达（G1与G3，p=0.020）。发现MT与Ki-67抗原表达之间存在正相关（r=0.32，p=0.019）。此外，MT表达与ER表达（r=-0.35，p=0.008）和PgR表达（r=-0.27，p=0.046）呈负相关。未检测到MT表达与HER-2表达之间的关系（r=0.12，p=0.37）。所得结果表明，MT表达可能有助于乳腺导管癌的预后评估。
